✨ Onyx Summary Perspective Therapeutics announced that the first patient has been treated in the second cohort of its Phase 1/2a trial evaluating [212Pb]PSV359, a targeted alpha radiopharmaceutical for solid tumors expressing FAP-α. The study advances dose escalation to 5.0 mCi following favorable safety review at lower
✨ Onyx Summary Ocugen will present at the 2025 Cell & Gene Meeting on the Mesa (Oct. 6, Phoenix), Chardan’s 9th Annual Genetic Medicines Conference (Oct. 21, New York), and the 2025 Maxim Growth Summit (Oct. 22, New York) to outline progress toward its goal of three BLAs in the
✨ Onyx Summary enGene Holdings granted inducement equity awards to four new employees, including Chief Medical Officer Hussein Sweiti, M.D., MSc, with options to purchase a total of 657,950 common shares at an exercise price of $6.83 per share. The grants, made under Nasdaq Listing Rule 5635(c)
✨ Onyx Summary enGene Holdings appointed Hussein Sweiti, M.D., MSc, as Chief Medical Officer, effective September 29, 2025. Dr. Sweiti, formerly Global Medical Head of Oncology Clinical Development at Johnson & Johnson, joins enGene as it transitions detalimogene voraplasmid toward regulatory filing and potential commercialization in high-risk, BCG-unresponsive
✨ Onyx Summary Massachusetts biotech leaders emphasized the importance of balancing drug affordability initiatives with the need to sustain innovation that drives future cures. As federal policymakers weigh new cost-control measures, the statement underscores that safeguarding both access and discovery is vital to ensure patients benefit not only from lower
✨ Onyx Summary Saama announced the launch of modular Clinical AI Agents built on its Agentic AI platform, enabling sponsors to drive efficiency and innovation across the clinical development lifecycle through partial autonomy and human-in-the-loop oversight. The purpose-built system addresses integration and compliance failures seen in generalist
✨ Onyx Summary Guardant Health announced FDA approval of its Guardant360® CDx as a companion diagnostic for Eli Lilly’s Inluriyo (imlunestrant), enabling identification of advanced or metastatic ER+, HER2– breast cancer patients with ESR1 mutations who may benefit from the therapy. This marks the test’s sixth FDA-approved companion
✨ Onyx Summary Guardant Health and Quest Diagnostics announced a multi-year strategic collaboration to make Guardant’s FDA-approved Shield™ blood test for colorectal cancer screening available through Quest’s vast provider network, patient service centers, and phlebotomy teams nationwide starting in early 2026. By pairing Shield’s simplicity with
✨ Onyx Summary Kyverna Therapeutics reported updated Phase 1 data from investigator-initiated trials of its CD19 CAR T-cell therapy, KYV-101, in progressive multiple sclerosis, showing favorable safety, CNS penetration, and early signs of disease stabilization or improvement. The data, presented by Stanford and UCSF at the 2025 ECTRIMS
✨ Onyx Summary Advanced Clinical announced that CEO Julie Ross has departed to pursue a new opportunity, with Founder and Owner Leo Sheridan assuming the role of Chief Executive Officer. Supported by a seasoned leadership team, the transition underscores the company’s continued focus on global growth, operational excellence, and delivering
✨ Onyx Summary Cellares appointed Chris McDonald, former SVP and Global Head of Technical Operations at Kite (a Gilead Company), to its Advisory Board. McDonald brings more than 35 years of experience scaling global biomanufacturing operations at Kite, Amgen, Novartis, and AstraZeneca, expertise that will support Cellares’ international expansion of its
✨ Onyx Summary Lexicon Pharmaceuticals announced that the FDA will require additional time to review newly submitted clinical data supporting the potential resubmission of its New Drug Application for Zynquista® (sotagliflozin) as an adjunct therapy for adults with type 1 diabetes, with feedback now expected in Q4 2025. The update follows
✨ Onyx Summary Adverum Biotechnologies announced it will complete screening by September 30 for ARTEMIS, its first pivotal Phase 3 trial of Ixo-vec in wet age-related macular degeneration (AMD), with full enrollment of at least 284 patients expected in 4Q 2025 and data readout in 1Q 2027. The ARTEMIS
✨ Onyx Summary MassBio and Google co-hosted the 2025 AI for Drug Discovery Training in Cambridge, bringing together more than 60 life sciences professionals from start-ups, academia, and pharma for hands-on sessions with Google’s Gemini and Vertex AI platforms. By equipping the Massachusetts biotech community with AI-
✨ Onyx Summary Geron Corporation granted inducement equity awards to 16 new hires totaling 966,000 shares—644,000 stock options at a $1.27 exercise price and 322,000 RSUs—under Nasdaq Listing Rule 5635(c)(4), with grants dated September 17, 2025 and four-year vesting schedules. The move
✨ Onyx Summary MassBio, SCbio, Venture Carolina, VentureSouth, and the South Carolina Department of Commerce launched the Palmetto Beacon Venture Fellowship, a program designed to educate and empower the next generation of biotech investors through immersive sessions in Charleston, John’s Island, and Boston. By bridging ecosystems from the Southeast to
